Drugs /

tpx-0131

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for tpx-0131

Tpx-0131 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating tpx-0131, 1 is phase 1/phase 2 (1 open).

ALK Fusion is the most frequent biomarker inclusion criterion for tpx-0131 clinical trials.

Non-small cell lung carcinoma is the most common disease being investigated in tpx-0131 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tpx-0131
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tpx-0131 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Target(s) [2]:
ALK

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.